Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 901: Nivolumab plus ipilimumab or nivolumab plus chemotherapy vs standard chemotherapy in first-line unresectable or metastatic urothelial cancer
2022-501784-40-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Nivolumab + Ipilimumab, Nivolumab + Gemcitabine + Platinum and Gemcitabine + Platinum (Standard of Care) (3 arms). Primary endpoints: Overall survival in cisplatin-ineligible randomized participants and Overall survival in PD-L1 positive (≥ 1%) randomized participants. Started Mar 2024; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2022-501784-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501784-40-00.